Genetic Predisposition for Chronic Non-specific Low Back Pain

Balgrist University Hospital100 enrolled

Overview

Patients with inflammatory back pain were shown to differ from healthy controls in genotype of the Angiotensin-converting enzyme (ACE), which regulates vasoconstriction/-dilatation. The aim of this study is to investigate whether genetic reduction of muscle perfusion might be a pathophysiological pathway of how genes influence chronic non-specific low back pain (LBP).

The following genes will be investigated: * Insertions-/deletions-polymorphism of the angiotensin-converting enzyme (ACE-I/D gene polymorphism; 3 genotypes: ACE-II, ACE-ID, ACE-DD). * Anti-adhesive extracellular matrix protein Tenascin-C: gene polymorphism rs2104772 The goals of this study are to investigate whether these genotypes correlate with 1) endurance of back muscles, 2) comorbidities such as asthma and diabetes and 3) the risk for LBP as assessed by a LBP-classification tool.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Low Back Pain

Interventions

no interventionOTHER

observational case-control study

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 18-65 Exclusion Criteria: * Spinal surgery * Spinal fracture * Inflammation * Tumour * Severe chronic disease which make intensive physical activity impossible (osteoporosis, cardiovascular heart diseases)

Locations (1)

Balgrist University Hospital

Zurich, Switzerland

Outcomes

Primary Outcomes

Polymorphism ACE Gene

Time frame: baseline

Polymorphism Tenascin Gene

Time frame: baseline

Secondary Outcomes

Back muscle endurance in Sorensen test

Time frame: baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.